ATE220688T1 - Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen - Google Patents
Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungenInfo
- Publication number
- ATE220688T1 ATE220688T1 AT91903963T AT91903963T ATE220688T1 AT E220688 T1 ATE220688 T1 AT E220688T1 AT 91903963 T AT91903963 T AT 91903963T AT 91903963 T AT91903963 T AT 91903963T AT E220688 T1 ATE220688 T1 AT E220688T1
- Authority
- AT
- Austria
- Prior art keywords
- enterotoxins
- tumor
- related compounds
- destructive effects
- destructive
- Prior art date
Links
- 231100000655 enterotoxin Toxicity 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 239000000147 enterotoxin Substances 0.000 title 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4648—Bacterial antigens
- A61K39/464821—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4648—Bacterial antigens
- A61K39/464822—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46657790A | 1990-01-17 | 1990-01-17 | |
PCT/US1991/000342 WO1991010680A1 (en) | 1990-01-17 | 1991-01-17 | Tumor killing effects of enterotoxins and related compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE220688T1 true ATE220688T1 (de) | 2002-08-15 |
Family
ID=23852299
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT91903963T ATE220688T1 (de) | 1990-01-17 | 1991-01-17 | Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen |
AT01102715T ATE303157T1 (de) | 1990-01-17 | 1991-01-17 | Verwendung von staphylococcus-enterotoxinen oder verwandte verbindungen für krebs-therapie |
AT01104586T ATE304371T1 (de) | 1990-01-17 | 1991-01-17 | Verwendung von staphylococcus enterotoxin homologe für krebs-therapie |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01102715T ATE303157T1 (de) | 1990-01-17 | 1991-01-17 | Verwendung von staphylococcus-enterotoxinen oder verwandte verbindungen für krebs-therapie |
AT01104586T ATE304371T1 (de) | 1990-01-17 | 1991-01-17 | Verwendung von staphylococcus enterotoxin homologe für krebs-therapie |
Country Status (5)
Country | Link |
---|---|
EP (3) | EP0511306B1 (de) |
AT (3) | ATE220688T1 (de) |
CA (1) | CA2078003C (de) |
DE (3) | DE69133485T2 (de) |
WO (1) | WO1991010680A1 (de) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8903100D0 (sv) † | 1989-09-20 | 1989-09-20 | Pharmacia Ab | New pharmaceutical agent |
US6042837A (en) * | 1989-09-20 | 2000-03-28 | Kalland; Terje | Methods of staphylococcal enterotoxin directed cell-mediated cytotoxicity (SDCC) |
US6126945A (en) * | 1989-10-03 | 2000-10-03 | Pharmacia Ab | Tumor killing effects of enterotoxins, superantigens, and related compounds |
US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
WO1993024136A1 (en) * | 1991-01-17 | 1993-12-09 | Terman David S | Tumor killing effects of enterotoxins, superantigens, and related compounds |
US5529934A (en) * | 1991-07-29 | 1996-06-25 | Biomide Investment Limited Partnership | Method for measuring blood procoagulant activity of human leukocyte antigens |
EP0626805A4 (en) * | 1992-01-28 | 1995-12-06 | Nat Jewish Ct Immun & Respirat | Protective effects of mutated superantigens. |
AU6358994A (en) * | 1993-03-02 | 1994-09-26 | David S. Terman | Method of cancer treatment |
US5585465A (en) * | 1993-04-05 | 1996-12-17 | National Jewish Center For Immunology And Respiratory Medicine | Isolated toxin associated with Kawasaki syndrome |
SE9402430L (sv) | 1994-07-11 | 1996-01-12 | Pharmacia Ab | Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten |
US5626838A (en) * | 1995-03-13 | 1997-05-06 | The Procter & Gamble Company | Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx |
US5935568A (en) * | 1995-05-18 | 1999-08-10 | National Jewish Medical & Research Center | Gene therapy for effector cell regulation |
SE9601245D0 (sv) | 1996-03-29 | 1996-03-29 | Pharmacia Ab | Chimeric superantigens and their use |
TW517061B (en) | 1996-03-29 | 2003-01-11 | Pharmacia & Amp Upjohn Ab | Modified/chimeric superantigens and their use |
IL119938A (en) | 1996-12-30 | 2005-08-31 | Yissum Res Dev Co | Peptides capable of eliciting protective immunity against toxic shock induced by pyrogenic exotoxins or of antagonizing toxin-mediated activation of t cells |
US6075119A (en) * | 1997-04-07 | 2000-06-13 | The Rockefeller University | Peptides useful for reducing symptoms of toxic shock syndrome |
US6872394B1 (en) | 1997-12-02 | 2005-03-29 | Idaho Research Foundation, Inc. | Non-toxic immune stimulating enterotoxin compositions |
CA2345023A1 (en) * | 1998-10-07 | 2000-04-13 | The Rockefeller University | Peptides useful for reducing symptoms of toxic shock syndrome and septic shock |
SE0102327D0 (sv) * | 2001-06-28 | 2001-06-28 | Active Biotech Ab | A novel engineered superantigen for human therapy |
JP7348074B2 (ja) * | 2017-06-04 | 2023-09-20 | ラパポート・ファミリー・インスティテュート・フォー・リサーチ・イン・ザ・メディカル・サイエンシーズ | がん治療に対する個別化応答の予測方法およびそのキット |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0287633B1 (de) * | 1986-10-16 | 1993-07-07 | The President And Fellows Of Harvard College | Kombinationen von nekrose-tumor-faktoren und entzündungshemmenden mitteln für die behandlung von bösartigen und nicht bösartigen erkrankungen |
SE8801426D0 (sv) * | 1988-04-15 | 1988-04-15 | Ulf Rothman | Forfarande och medel for blodbehandling |
SE8903100D0 (sv) * | 1989-09-20 | 1989-09-20 | Pharmacia Ab | New pharmaceutical agent |
-
1991
- 1991-01-17 EP EP91903963A patent/EP0511306B1/de not_active Revoked
- 1991-01-17 WO PCT/US1991/000342 patent/WO1991010680A1/en not_active Application Discontinuation
- 1991-01-17 EP EP01104586A patent/EP1129717B2/de not_active Expired - Lifetime
- 1991-01-17 DE DE69133485T patent/DE69133485T2/de not_active Expired - Lifetime
- 1991-01-17 DE DE69133068T patent/DE69133068T2/de not_active Revoked
- 1991-01-17 DE DE69133484T patent/DE69133484T2/de not_active Expired - Fee Related
- 1991-01-17 CA CA002078003A patent/CA2078003C/en not_active Expired - Lifetime
- 1991-01-17 AT AT91903963T patent/ATE220688T1/de active
- 1991-01-17 AT AT01102715T patent/ATE303157T1/de not_active IP Right Cessation
- 1991-01-17 EP EP01102715A patent/EP1103268B1/de not_active Expired - Lifetime
- 1991-01-17 AT AT01104586T patent/ATE304371T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP0511306A1 (de) | 1992-11-04 |
DE69133485T2 (de) | 2006-06-22 |
CA2078003A1 (en) | 1991-07-18 |
DE69133484T2 (de) | 2006-05-18 |
ATE303157T1 (de) | 2005-09-15 |
WO1991010680A1 (en) | 1991-07-25 |
DE69133484D1 (de) | 2005-10-06 |
EP1129717A1 (de) | 2001-09-05 |
EP1129717B2 (de) | 2013-03-06 |
EP1103268B1 (de) | 2005-08-31 |
EP0511306A4 (en) | 1993-04-28 |
CA2078003C (en) | 2006-11-21 |
EP1103268A1 (de) | 2001-05-30 |
EP1129717B1 (de) | 2005-09-14 |
DE69133068D1 (de) | 2002-08-22 |
DE69133068T2 (de) | 2003-03-13 |
ATE304371T1 (de) | 2005-09-15 |
EP0511306B1 (de) | 2002-07-17 |
DE69133485D1 (de) | 2005-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE220688T1 (de) | Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen | |
NO893769L (no) | Fremgangsmaate for behandling av naturgass. | |
HUP9802212A2 (hu) | Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok | |
ATE178907T1 (de) | Rezeptorbindende region des diphtherietoxius | |
BG101118A (en) | Therapeutical compounds | |
DE69110785D1 (de) | Narkosemittelverdampfer. | |
ES2063515T3 (es) | Ifn-alfa o-glucosilados. | |
NO307968B1 (no) | Pyrazolo- og pyrrolopyridiner og farmasøytisk blanding derav | |
ATE148130T1 (de) | Typ-iv-dipeptidyl-aminopeptidase-inhibitoren | |
DE69327534D1 (de) | Impfstoffe gegen diphtherietoxin | |
DK0605442T3 (da) | Rekombinante antistoffer til human terapi | |
PT723538E (pt) | Compostos triciclicos de carbamato uteis para a ainibicao da funcao da proteina g e para o tratamento de doencas proliferativas | |
SE9704546D0 (sv) | Novel compounds | |
NO972451L (no) | Heterosyklyloksy- og tiometyl-1,2,5-tiadiazolidin-3-on 1,1-dioksyder og preparater og fremgangsmåte for anvendelse derav | |
NO910340D0 (no) | Topiske preparater for behandling av menneskenegler. | |
DK0648503T3 (da) | Pro-prodrugs, deres fremstilling og anvendelse | |
DE69309044D1 (de) | Behandlung von asthma | |
DE69434384D1 (de) | Metalkomplexbildner | |
DE69530844D1 (de) | Verfahren und substanzen gegen protozoen | |
NO973548L (no) | Behandling av diabetisk neuropati | |
NO911429D0 (no) | Stoffbehandling. | |
NO179855C (no) | Fremgangsmåte for fremstilling av et legemiddel | |
FI890864A0 (fi) | Anvaendning av 1,4-dihydropyridinderivat. | |
ATE107165T1 (de) | Verwendung von macrolactonen als antiallergica. | |
DE59107762D1 (de) | Komplexe, enthaltend S(+)-Phenyl-alkansäuren und alpha-Hydroxy-alkansäuren |